May 21, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) versus investigator's choice of chemotherapy as first‑line treatment for unresectable l

Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. In order to get its hands on InnocsAI’s pipeline of oncology therapies—which includes one candidate en route to the clinic—California-based Liminatus is stumping up 1.6 billion of its shares priced at 20 cents apiece, according to a Securities and Exchange Commission filing. As well as the shares, InnocsAI’s owners will receive a contingent value right to 20% of the proc

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to improve access to life-saving diagnost

May 20, 2026 -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the outstanding equity in SPR. The acquisition continues Medtronic's momentum in driving st

The Xofluza license deal between Roche and the Medicines Patent Pool comes as ongoing hantavirus and Ebola outbreaks have once again thrust pandemic preparedness into the spotlight. (Roche/Genentech) Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza (baloxavir marboxil) for generic drugmakers to copy in 129 developing countries. The deal with the Medicines Patent Pool will enable generic supply of baloxavir in 129 low- and middle-income count

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate (ADC) that could have better luck binding to tricky target sites. At the center of the deal is Parabilis’ Helicon peptide platform. Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets. Their superpower is the ability to attach to flat surfaces that would otherwise make traditional small-mo

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address the over decade long unresolved BCG shortag

The research collaboration will be the first ever to focus on space-based drug formulation that could result in therapies for patients. May 13, 2026 -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease. Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of small molecule medicines for p

Rigel gets hands on Pfizer's recently-approved breast cancer drug Bayer cuts early-stage assets from pipeline Superior weight loss in Wegovy HD early responders 'First-of-its-kind' collab aims to incubate new biotechs Rigel gets hands on Pfizer's recently-approved breast cancer drug Having signalled their intent last year to find a US commercialisation partner for vepdegestrant, Pfizer and Arvinas reached an agreement with Rigel Pharmaceuticals on Tuesday to both market and further develop the

LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist’s DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers’ and partners’ AI models faster. “AI can design new protein molecules for biologic drug